SCHEMBL21940889

SCHEMBL21940889

CC(C)(C)OC(=O)N1CC2(Cc3ccccc3C2)C1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.50
CYP11B2 P19099 1/20 0.46
NAMPT P43490 4/20 0.46
GPR119 Q8TDV5 2/20 0.45
SCD5 Q86SK9 1/20 0.45
RORC P51449 2/20 0.43
NR1H2 P55055 2/20 0.42
ESR2 Q92731 1/20 0.42
CHRM2 P08172 1/20 0.41
CHRM4 P08173 1/20 0.41
CHRM1 P11229 1/20 0.41
CHRM3 P20309 1/20 0.41
BCHE P06276 1/20 0.41
GPR183 P32249 1/20 0.41
KDM4E B2RXH2 1/20 0.40
PKM P14618 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29609197 1.00 MAPK1 (0.50) MAPK1CYP11B2NAMPTGPR119SCD5
SCHEMBL29609790 0.85 MAPK1 (0.51) MAPK1CYP11B2NAMPTGPR119SCD5
SCHEMBL23902054 0.85 MAPK1 (0.51) MAPK1CYP11B2NAMPTGPR119SCD5
SCHEMBL23051561 0.82 GPR119 (0.41) CYP11B2GPR119SCD5RORCNR1H2
SCHEMBL23051565 0.81 SCD5 (0.40) CYP11B2GPR119SCD5NR1H2ESR2
SCHEMBL6114857 0.80 USP2 (0.43) CYP11B2SCD5NR1H2GPR183KDM4E
SCHEMBL18706580 0.80 MAPK1 (0.52) MAPK1NAMPTGPR119RORCNR1H2
SCHEMBL1394450 0.79 USP2 (0.52) CYP11B2GPR119RORCNR1H2CHRM2
SCHEMBL10111760 0.79 GPR119 (0.59) MAPK1CYP11B2NAMPTGPR119SCD5
SCHEMBL17645954 0.79 USP2 (0.42) CYP11B2SCD5NR1H2GPR183KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240024346-A1 CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF RISEN SUZHOU PHARMA TECH CO LTD (CN) 2024-01-25 US disclosed
US-20240024346-A1 CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF RISEN SUZHOU PHARMA TECH CO LTD (CN) 2024-01-25 US disclosed
US-20240024346-A1 CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF RISEN SUZHOU PHARMA TECH CO LTD (CN) 2024-01-25 US disclosed
US-20230295213-A1 CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF RISEN SUZHOU PHARMA TECH CO LTD (CN) 2023-09-21 US disclosed
US-20230295213-A1 CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF RISEN SUZHOU PHARMA TECH CO LTD (CN) 2023-09-21 US disclosed
US-20230295213-A1 CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF RISEN SUZHOU PHARMA TECH CO LTD (CN) 2023-09-21 US disclosed
EP-3867238-B1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS ARRAY BIOPHARMA INC (US) 2023-06-07 EP disclosed
WO-2022109741-A1 CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2022-06-02 WO disclosed
WO-2020081848-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2020-04-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295213-A1 CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF ENTPD5, NT5E, ENTPD1 MAPK1 4022/4885CYP11B2 3022/4885NAMPT 27/4885
US-20240024346-A1 CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF ENTPD5, NT5E, ENTPD1 MAPK1 4022/4885CYP11B2 3022/4885NAMPT 27/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.